2020
A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC).
Veeraraghavan J, Gutierrez C, De Angelis C, Wang T, Pascual T, Weigelt B, Galvan P, Rexer B, Forero-Torres A, Wolff A, Nanda R, Storniolo A, Krop I, Goetz M, Reis-Filho J, Hilsenbeck S, Prat A, Osborne C, Schiff R, Rimawi M. A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC). Journal Of Clinical Oncology 2020, 38: 1011-1011. DOI: 10.1200/jco.2020.38.15_suppl.1011.Peer-Reviewed Original ResearchPIK3CA mutation statusBreast cancerHER2 ratioMutation statusPathologic complete response rateIntratumor heterogeneityRate of CTXComplete response rateData cohortDe-escalation strategiesLT therapyEvaluable patientsUnselected patientsClinical trialsTargeted therapyProspective validationHER2 geneResponse rateAdditional casesHER2PatientsHER2 proteinCohortPAM50Protein levels
2017
GRB7 Expression and Correlation With HER2 Amplification in Invasive Breast Carcinoma
Bivin W, Yergiyev O, Bunker M, Silverman J, Krishnamurti U. GRB7 Expression and Correlation With HER2 Amplification in Invasive Breast Carcinoma. Applied Immunohistochemistry & Molecular Morphology 2017, 25: 553-558. PMID: 26945445, DOI: 10.1097/pai.0000000000000349.Peer-Reviewed Original ResearchConceptsInvasive breast carcinomaHER2 amplificationHER2 overexpressionER negativityPathologic stageHistologic gradeP53 positivityGRB7 expressionBreast cancerBreast carcinomaInvasive breast cancer correlatesInvasive breast cancerBreast cancer correlatesChromosome 17 copy numberAntiestrogen therapyPR expressionPredictive factorsHER2 expressionCancer correlatesPR testingP53 immunohistochemistryAggressive phenotypeHER2 geneHER2P53 status
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply